959471-24-0

Upstream product

• 2039-82-9 1-bromo-4-ethenyl-benzene 
• 67-64-1 acetone 
• 108-86-1 bromobenzene 
• 20201-26-7 ethyl 4-bromophenylglyoxylate 
• 92093-23-7 1-(4-bromophenyl)ethane-1,2-diol 
• 77-76-9 2,2-dimethoxy-propane 

Downstream Products

• 1334204-38-4 C₁₄H₁₈O₂ 
• 1334204-49-7 C₂₂H₃₃BO₂ 
• 1334204-58-8 C₁₅H₂₀O₄ 
• 1147392-40-2 (2R)-1-(2-(4'-(2,2-dimethyl-1,3-dioxolan-4-yl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine 

Relevant academic research and scientific papers

Enhanced brightness emission-tuned nanoparticles from heterodifunctional polyfluorene building blocks

Three-coordinate complexes (bromo)[4-(2,2-dimethyl-1,3-dioxolan-4-yl)- phenyl](tri-tert-butyl-phosphine)palladium (1) and (bromo){4-[(tetrahydro-2H- pyran-2-yloxy)methyl]phenyl}(tri-tert-butyl-phosphine)palladium (2) were used to initiate Suzuki-Miyaura chain growth polymerization of 7′-bromo-9′, 9′-dioctyl-fluoren-2′-yl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (3). The polymerization was optionally terminated by end-capping with red-emitting N-(2-ethylhexyl)-1,6-bis(4-tert-octylphenoxy)-9-(4,4,5,5- tetramethyl-[1,3,2]dioxaborolan-2-yl)-perylene-3,4-dicarboximide. Heterodisubstituted polyfluorenes of adjustable molecular weights between 5 × 103 and 1.0 × 104 g mol-1 and narrow molecular weight distribution (Mw/Mn n = 2 × 103 g mol-1) to the reactive end groups yielded amphiphilic block copolymer, which afforded stable nanoparticles with diameters in the range of 25-50 nm when dispersed in water. These particles exhibited a bright fluorescence emission with quantum yields as high as Φ = 84%, which could optionally be tuned to longer wavelengths by energy transfer to the perylene monoimide dye. The heterodifunctional nature of these polyfluorenes is crucial for a bright and enduring fluorescence brightness as revealed by comparison to nanoparticles containing physically mixed dye. Further addition of terrylene diimide dye to the nanoparticles of perylene-end-capped polyfluorene block copolymers allows for an energy cascade resulting in emission exclusively in the deep red and near-infrared regime.

Controlling Selectivity in Alkene Oxidation: Anion Driven Epoxidation or Dihydroxylation Catalysed by [Iron(III)(Pyridine-Containing Ligand)] Complexes

A highly reactive and selective catalytic system comprising Fe(III) and macrocyclic pyridine-containing ligands (Pc-L) for alkene oxidation by using hydrogen peroxide is reported herein. Four new stable iron(III) complexes have been isolated and characterized. Importantly, depending on the anion of the iron(III) metal complex employed as catalyst, a completely reversed selectivity was observed. When X=OTf, a selective dihydroxylation reaction took place. On the other hand, employing X=Cl resulted in the epoxide as the major product. The reaction proved to be quite general, tolerating aromatic and aliphatic alkenes as well as internal or terminal double bonds and both epoxides and diol products were obtained in good yields with good to excellent selectivities (up to 93 % isolated yield and d.r.=99 : 1). The catalytic system proved its robustness by performing several catalytic cycles, without observing catalyst deactivation. The use of acetone as a solvent and hydrogen peroxide as terminal oxidant renders this catalytic system appealing.

COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT

Compounds and compositions useful for treating disorders related to Kit are described herein.

BIPHENYL DERIVATIVES AS MODULATORS OF THE HISTAMINE-H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

Biphenyl derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the H3 histamine receptor. (Ia) Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders, such as cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness, such as narcolepsy, shift-work syndrome, drowsiness as a side effect from a medication, maintenance of vigilance to aid in completion of tasks and the like, cataplexy, hypersomnia, somnolence syndrome, jet lag, sleep apnea and the like, attention deficit hyperactivity disorder (ADHD), schizophrenia, allergies, allergic responses in the upper airway, allergic rhinitis, nasal congestion, dementia, Alzheimer's disease, pain and the like.